Acute myeloid leukaemia in the elderly is a disease with distinct biological properties, commonly associated with leukaemic cell treatment resistance and with an increased number of high-risk features, including concomitant myelodysplasia and poor-risk cytogenetic abnormalities such as monosomy 5 and 7. Complete remission rates after standard induction chemotherapy in patients above age 60 years are less than 50%, with long-term survival rates below 10%. Post-remission stem cell transplant therapies have not been studied extensively. Autologous transplants can result in an acceptable 3-year leukaemia-free survival rate of up to 47%, yet this procedure is applicable only to a small minority of patients. Myeloablative allogeneic transplants similarly show feasibility in selected few patients and in general are very toxic. Non-myeloablative allogeneic transplants are associated with reduced toxicity, but are plagued by an increased relapse rate. The latter strategy appears promising, but must be validated in larger, multi-centre prospective trials, in which outcomes are compared to non-transplant approaches.
Introduction
Acute myeloid leukaemia (AML), untreated a universally fatal disease, results from a somatic mutation in a haematopoietic stem cell or a more differentiated myeloid cell, 1 leading to accumulation of non-functioning blast cells. The incidence of AML increases with age and over 50% of patients presenting with de novo AML are over age 60 years. 2 The median age at diagnosis is approximately 65 to 70 years 3 and individuals over age 70 years have a 12-fold higher incidence of de novo and secondary AML than younger individuals. Survival after therapy depends on disease-related factors including cytogenetic risk and presence of secondary AML, as well as patient-related factors including comorbidities and advancing age. A number of studies have shown uniformly worse outcomes for older patients, regardless of treatment as compared to patients diagnosed and treated at younger age. [4] [5] [6] [7] Older patients appear to be less tolerant to the dangers of prolonged cytopenias as well as the side effects of intensive anti-leukaemia therapy. 8 Anthracycline and cytarabine regimens given to patients over age 60 years result in complete remission (CR) rates less than 50% and long-term survival rates are well below 10%, 9 data significantly inferior to younger patients. Such poor outcomes in the elderly largely are related to: (1) patient-related factors, that is, decreased performance status, higher susceptibility to complications related to prolonged periods of neutropenia and diminished baseline visceral organ function and (2) a more aggressive disease biology. 10 A major challenge in the field of haematology-oncology is to improve upon outcomes of elderly AML patients. This article will review disease biology and treatment results, using conventional chemotherapy in elderly AML patients and focus on stem cell transplantation and provide recommendations.
Biology of AML in the elderly
Leukaemic cells of elderly AML patients exhibit biologic differences when compared to those derived from younger patients. 11 Older patients often present with morphological features of marrow dysplasia as well as higher rates of antecedent myelodysplastic syndrome as compared to younger patients. 12 This finding may provide support for the hypothesis that leukaemic cells in older patients appear to emerge from a more proximal pluripotent stem cell, which divides more slowly and therefore is more resistant to cytotoxic therapy. 9 In addition, it has been demonstrated that cells obtained from older AML patients have lower apoptotic rates in in vitro culture than younger patients. 13 Importantly, older patients tolerate chemotherapy less well due to antecedent comorbid conditions, decreased drug clearance and decreased tolerance of normal stem cells to myelosuppressive chemotherapy. 14 Cytogenetics of the leukaemic cell remain the most important risk factor for patient outcome. A recent retrospective analysis of 968 adult AML patients, reported by Appelbaum et al., 15 examined changes in AML cell biology with increasing age. The percentage of patients with favourable cytogenetics dropped from 17% in patients younger than age 56 years to 4% in subjects older than 75 years. Further, the proportion of patients with unfavourable risk cytogenetics increased significantly from 35% in the younger age group to 51% in older patients. A higher proportion of the blasts in the older patients (34%) had loss of part or all of chromosomes 5 and 7 compared to 12% in younger patients. Similar results were obtained previously and reported by the MRC group in the United Kingdom. 16 Leukaemic cells obtained from elderly AML patients are more likely to display resistance to cytotoxic chemotherapy, thought to be related mainly to an overexpression of the multi-drug resistance glycoprotein 1 (MDR1). Leith et al.
12 demonstrated in their study of 211 AML patients that the elderly had a high frequency of MDR1 expression (71%) and functional drug efflux (58%). These features were associated with poor outcomes and suggested a distinct biologic resistance mechanism compared to younger patients. 12 Multi-drug resistance measured in the study by Appelbaum and et al. 15 was present in one-third of AML patients younger than 56 years but expressed in 57-62% of patients with higher age categories. Other regulators of drug efflux, that is, multi-drug resistanceassociated protein and lung resistance protein also have been implicated in higher resistance of leukaemic blast cells. 17, 18 Other investigators have reported that gene mutations (p53) and overexpression (BCL2) may contribute to multi-drug resistance in AML patients. 19 Finally, it has been postulated that a small number of mutational events may account for the development of AML in younger patients whereas, in the elderly, several events may occur, leading to development of multiple drug resistance mechanisms. 15, 20 Other risk factors such as a CD34 stem cell phenotype and antecedent haematological disease are present more frequently in older patients with AML, as compared to younger patients, accounting for differences in outcomes compared with younger patients.
Conventional treatment

Induction chemotherapy
The goal of induction chemotherapy in AML is to decrease tumor load and obtain CR of the disease. The decision to proceed with induction chemotherapy in the elderly AML patient, however, is difficult because of significantly increased toxicity and a lower chance of obtaining CR, 14 as compared to younger patients. Standard induction chemotherapy CR rates are significantly inferior in the elderly AML patient (40-50%) versus 75% in younger patients and treatment-related mortality (TRM) remains high at approximately 25%. 21 Two randomized trials reported nearly two decades ago in older AML patients compared aggressive induction chemotherapy with alternative low-dose treatment approaches. Tilly et al., 22 in a randomized manner, administered to patients over age 65 years either daily cytarabine 20 mg/m 2 for 21 days versus rubidazone 100 mg/m 2 /day for 3 days and cytarabine 100 mg/m 2 /day for 7 days. Although CR rates were higher in the intensive arm, TRM was higher (31 versus 10%) and overall survival (OS) did not differ in the two groups. On the other hand, Lowenberg et al. 23 reported statistically significant longer OS in patients of at least age 65 years receiving induction chemotherapy with daunorubicin, vincristine and cytarabine, versus supportive care and low-dose chemotherapy (either hydroxyurea or cytarabine). Median survival was 21 versus 11 weeks and projected survival at 2.5 years was 13 versus 0%. These poor survival results remain unchanged even in the modern supportive care era when, for example, G-CSF treatment is added to standard supportive care. 24, 25 CR duration in older adults is short, the probability of disease-free survival (DFS) in patients attaining CR approximately 15-20% at 3 years and is below 10% for the entire group of patients. 14, 26 A more efficient strategy may be to identify prognostic factors pre-induction, in order to select patients who have a higher chance of better outcome versus those not likely to benefit from induction chemotherapy. Kantarjian et al. 27 recently published a predictive albeit retrospective prognostic model for outcome in 998 AML or high-risk myelodysplastic syndrome (MDS) patients (median (range) age 71 (65À89) years) given induction chemotherapy. Overall CR rate and induction mortality for the whole group were 45 and 29%, respectively. Adverse prognostic factors included age 475 years, poor performance status (ECOG42), unfavourable karyotype, treatment administered in the absence of laminar airflow rooms, anaemia (Hbo80 g/l), leucocytosis (425 Â 10 9 /l), serum creatinine 41.3 mg/dl, antecedent haematologic disorder (46 months) and prior therapy for other cancers. High CR rates (470%) were obtained if the patients exhibited 0-1 adverse prognostic factors, while CR rates were o20% if four or more adverse factors were present. Analyses for 8-week mortality and OS similarly showed the utility of these predictors.
The decision to use induction chemotherapy in an elderly patient remains a dilemma and reflects significant inherent patient selection bias. Obviously those subjects who are not thought to be candidates for induction chemotherapy should be enrolled into study protocols, using new approaches that utilize novel agents or targeted therapies.
Post-remission therapy
It is unclear which, if any, post-remission treatment is optimal for elderly AML patients. 21 Lowenberg et al.
28
compared either low-dose cytarabine versus observation in older AML patients who achieved remission using aggressive induction chemotherapy. DFS was superior in the cytarabine arm; however, no difference in OS was noted. CALGB protocol 8525 compared three dose intensity levels of cytarabine consolidation. Remarkably, no differences were noted in DFS for patients age over 60 years (DFS ¼ 14%), and those given the more intense consolidation regimens experienced more toxicity. 14 [29] [30] [31] [32] Such trials traditionally have not included elderly patients, despite the consensus that toxicity of autotransplantation is considerably less as compared with allogeneic transplant. Four large intergroup trials compared allogeneic transplant versus autologous transplant versus chemotherapy treatment. In three studies, the upper age limit was 55 years and was 50 years in the fourth. Autotransplant TRM was 3-14% compared to 17-25% in allografts and 3-7% with conventional chemotherapy. [29] [30] [31] [32] On the other hand, relapse rates were highest in the chemotherapy groups (55-61%), followed by the autotransplant group (35-48%); for a variety of reasons, disease recurrence rates were lowest in the allografts at 24-33%. CR1 poor-risk cytogenetics group patients benefited the least from autograft when analysing these trials. Further, CR1 patients relapsing after an autotransplant had a low probability of achieving CR2. 33 A variety of practitioners interpret these data to offer autografting only for CR1 AML patients who have intermediate risk cytogenetics and are without a HLA matched-sibling donor.
Can an older patient tolerate an invasive procedure like an autologous stem cell transplant? Feasibility of this procedure in patients older than age 60 years has been demonstrated by a number of smaller reports investigating patients between the ages of 61-76 years, 34 61-68 years 35 and 61-65 years, 36 undergoing autologous stem cell transplant predominantly for multiple myeloma and nonHodgkin lymphoma (NHL). An acceptable TRM within the first 100 days of between 0 and 17% was noted in these elderly patient studies. Table 1 reviews the data for the studies that investigated the role of autologous stem cell transplantation specifically in the elderly AML patient. [37] [38] [39] [40] [41] [42] [43] Cahn et al. 37 retrospectively compared European Group for Blood and Marrow Transplantation (EBMT) data for 111 CR1 AML patients older than 50 years versus 786 younger (median age 35 years) patients. Leukemia free survival (LFS) and OS rates at 4 years were significantly inferior in older patients, 34 versus 43% (P ¼ 0.004) and 35 versus 48% (P ¼ 0.004), respectively. The probability of relapse did not differ (52 versus 58%), but TRM was higher in the older age group at 28 versus 14% (Po0.0001). These data suggested that elderly AML patients tolerated the autotransplants less well, yet some viable, older candidates can be identified and given transplant procedures successfully. A second retrospective registry data analysis by the Acute Leukemia Working Party of the EBMT published by Gorin et al. 38 examined the feasibility of autotransplantation in AML patients older than 60 years. A total of 193 patients aged 60-75 (median age 63) years received autografts between the period 1984-1998, 147 of whom were in CR1. Cytogenetic results were available only in 85 patients (and were normal in 67 subjects). Median (range) follow-up was 14 months (1-100) and most received peripheral blood as the stem cell source. Three-year TRM for all patients was 16% (15% for CR1 patients). For the CR1 patients, the incidence of relapse was 58%, LFS 46% and OS 47%. Interestingly, usage of marrow grafts was associated with a higher relapse rate as compared to blood as the stem cell source, 44 versus 63%, P ¼ 0.04. Further, these elderly patients who received transplants after 1996 had significantly better LFS (41 versus 65%, P ¼ 0.02). These results support the current use of blood stem cell transplants in older AML patients in remission but must be viewed with caution given the retrospective nature of registry data and its limitations including inherent patient selection bias.
Autologous stem cell transplantation for AML: results in the elderly
Ferrara et al. 39 reported a single-centre study investigating feasibility of performing autografts a median of 3 months after CR was attained in 22 elderly AML patients. Median (range) age was 64 (61-71) years; 20 were in CR1, two in CR2 and 13 had normal cytogenetics. At a median follow-up of 12 months, one patient died of TRM (5%) and 13 died from relapse. Median DFS was 14 months and 9 patients (41%) were alive at 1 year. Follow-up is short and these patients are highly selected but the results appear quite promising.
The Catalan Leukemia group CETLAM conducted a non-randomized trial 41 in AML patients older than 60 years, in which, over a 4-year period, 258 patients were registered; 135 (52%) were enrolled for intensive treatment. The remainder were excluded due to a diagnosis of APL, secondary AML, poor performance status or left ventricular ejection fraction on multiple gated blood pool imaging (MUGA) scan o50%. Further, patients who had unacceptable toxicity during induction or those with medical comorbidities were excluded from transplant. Conditioning for the autotransplant included cyclophosphamide/TBI or busulfan/cyclophosphamide. Of the initial 135 patients enrolled for aggressive treatment, only 16 patients (median (range) age 64 (61-70) years) underwent autotransplantation. Median survival of this small group was 28 months and the 2-year estimated probability of OS and LFS were 47 and 39%; for those candidates not receiving transplants, LFS was 22% (P ¼ 0.07). TRM of those transplanted was 19%. Early relapse (15%) and failure to mobilize (17%) were major causes of failure to proceed to autologous transplant. A total of 27% of patients had to be withdrawn before transplant, because of confounding medical conditions. Patients with poor-risk cytogenetics, older age (above 70 years) and marked leukocytosis at presentation had statistically significant Stem cell transplant in elderly AML TL Kiss et al (61-94) ) years. Ninety of 155 (58%) patients were judged to be eligible for induction chemotherapy and 45 of those (50%) treated had achieved CR. Thirty-six subjects subsequently received consolidation therapy and 32 were given mobilization treatment that facilitated blood stem cell collection in 25 individuals; ultimately 20 patients received an autologous transplant. Median survival was 4 months for the entire patient population and 19 months for patients actually autografted that included subjects up to the age of 77 years. The finding that only 13% of the initial population went on to receive an autotransplant is consistent with other studies that reported feasibility rates of 12, 6 and 6% of elderly AML patients. [40] [41] [42] The outcomes for these feasibility studies in particular are depicted in Table 2 .
Mobilization issues
Stem cell mobilization usually is successful after G-CSF treatment alone or in combination with chemotherapy. Some investigators speculate as to the stem cell toxicity of induction and consolidation regimens that contain anthracyclines, fludarabine or combinations. 43 The optimal timing of stem cell collection in relation to consolidation, that is, in vivo purging effect, 33 also remains an unresolved question. Further, no firm recommendations can be made as to the stem cell source, as one study purports to show better results with marrow as compared to peripheral blood. 33 Preparative regimens for autografting likely should contain myeloablative doses of combination chemotherapy, that is, higher relapse rates are associated with single-agent conditioning regimens. 40 Conclusions regarding the role of autografting in elderly AML patients remain guarded. Those in whom the procedure appears feasible are a highly selected group, usually subjects who do not have unfavourable risk cytogenetics, are in CR1, are devoid of comorbid conditions, have a good performance status, are able to proceed to consolidation and mobilization and subsequently receive a transplant. For a variety of reasons, a prospective, randomized trial comparing autotransplant to conventional therapy likely will never be completed. The decision to proceed to an autograft reflects the bias of investigators and patients and does not appear to be founded on hard data.
Myeloablative allogeneic stem cell transplantation
Elderly patients experience higher toxicity rates and poorly tolerate myeloablative conditioning so that most Table 3 . The Seattle group 44 investigated myeloablative conditioning in allogeneic transplantation in 52 leukaemia and MDS patients older than 60 years of age (median age 62.8 years). Myeloablation consisted of busulfan/cyclophosphamide in 35 patients, cyclophosphamide/TBI in 11, fludarabine/busulfan in five and cyclophosphamide alone in one patient. Non-relapse mortality at 100 days and three years was 27 and 43%, respectively; at a median follow-up of 4.6 years, 18 of 52 patients survive. Of note, all advanced AML and CML patients died compared to improved outcome in patients with less advanced disease. As anticipated, outcomes were improved in patients transplanted after 1993. The authors concluded that this approach in the elderly-age population should only be considered in selected patients who do not have advanced disease status. Similar results were obtained by the Essen group report 45 of 215 patients median (range) age 57 (50-67) years who received a myeloablative allograft from a matched-related (57%) or unrelated (43%) donor. TRM at 1 year was 30% in early-stage disease (CML first chronic phase or non-transformed MDS) versus 49% in advanced-disease patients. The Dana Farber group compared in patients older than 50 years myeloablative transplants, using cyclophosphamide/TBI versus nonmyeloablative transplants prepared with fludarabine and busulfan conditioning. They described 152 patients, including 66 AML or MDS patients. TRM favoured the nonmyeloablative approach, 6 versus 30% at 100 days and a cumulative incidence of 32 versus 50%. 46 The MD Anderson group treated 56 patients older than age 55 (median 58) years on two consecutive protocols between 1997 and 2004. 47 Diagnoses included MDS (n ¼ 13), AML (n ¼ 33) or CML and other myeloproliferative disorders. Conditioning included fludarabine 40 mg/m 2 and busulfan 130 mg/m 2 (n ¼ 36) or busulfan 0.8 mg/kg for 16 doses and cyclophosphamide 120 mg/kg. A total of 40% of the grafts was obtained from unrelated donors. TRM at 100 days and 1 year was 11 and 29%, respectively. Acute and chronic GVHD rates appeared to be increased with advancing age (38 versus 64% acute and 45 versus 54% chronic GVHD). Major causes of treatment failure were GVHD and disease relapse, although 68% of patients were not in CR at time of transplant. The IV busulfan and fludarabine conditioning regimen, however, was well tolerated in the older age group. The EBMT reported a retrospective comparison of AML patients older than age 50 years receiving an HLA identical sibling transplant after reduced-intensity conditioning (RIC) (n ¼ 315) versus a myeloablative regimen (n ¼ 407). 48 In multivariate analysis, acute GVHD (II-IV) (22 versus 31%, P ¼ 0.01) and TRM were significantly decreased in the RIC group (18 versus 32%, P ¼ 0.00006). Two-year OS and LFS rates, however, were equal in the two groups (47 versus 46%, and 40 versus 44%). Such studies suggest that myeloablative transplants in elderly patients are feasible in only a minority of patients. RIC regimens appear to provide less disease control than myeloablative regimens, but are associated with a reduced TRM. Fludarabine and busulfan containing preparative regimens appear to have less toxicity in the older patient age group.
Non-myeloablative allogeneic stem cell transplantation
A number of studies, albeit non-randomized, are emerging, that address the strategy of RIC allogeneic transplantation in elderly AML patients (Table 4) . McSweeney et al. 49 for the Seattle group used a single-fraction 200 cGy TBI preparative regimen followed by cyclosporine and mycophenolate mofetile GVHD prophylaxis in 45 haematologic malignancy patients (median age 56 years) that included 10 subjects with AML. Non-relapse and relapse mortality were 6.7 and 26.7%, respectively, with a median follow-up of 417 days. Five of six CR1 AML patients remained in remission, whereas both advanced disease AML patients died, one each from disease progression and the other due to infection. Engraftment failure was noted in 20% of patients and fludarabine subsequently has been added to counteract this drawback. 50 That group later reported on 18 CR1 AML patients, median age 59 (36-73) years, given blood stem cell transplants obtained from HLA identical siblings. At a median follow-up of 21 months, 10 patients have died, seven due to disease progression and three due to treatment. Estimated 1-year TRM was 17% and OS at 2 years was 45%. The Spanish group 51 reported a prospective RIC study using fludarabine and busulfan in AML (n ¼ 17) and MDS (n ¼ 20) advanced-disease patient median (range) age 57 years. One-year probability of relapse mortality and disease progression were 5 and 28%, respectively. The same investigators addressed the use of targeted-dose versus non-targeted oral busulfan in the setting of RIC transplants in an updated publication; 50 these investigators found no difference. The Freiburg group 53 reported an 'intense RIC' protocol using fludarabine, melphalan and carmustine in elderly AML patients median (range) age 64 (60-70) years. One-year TRM and PFS were 22 and 61%, despite the fact that a number of patients received transplants in an advanced-disease state. These favourable outcomes were confirmed in an update. 54 Such studies indicate that RIC transplants may be feasible in selected elderly AML patients. On the other hand, such results suggest that somewhat more intense conditioning regimens may be necessary to prevent disease progression rate after transplant.
More recent reports with longer follow up of patients receiving a RIC approach in elderly AML patients are encouraging. Hegenbart et al. 55 presented a multi-centre study using fludarabine and low-dose TBI conditioning in 122 AML patients representing an extended and updated report to the Seattle group trials. 49, 50 Median patient age was 57.5 years and 48% of subjects received related versus 52% unrelated grafts. A total of 42% were in CR1 at transplant and 74% received a RIC transplant, as they were thought not to be eligible for a myeloablative treatment, based on advanced age. 55 At a median follow-up of 44 months, 100-day and 1-year non-relapse mortality were at 3 and 14%, respectively. At 2 years, the probability for OS Wong et al. 57 at the MD Anderson Cancer Center published their experiences with 29 patients (13 with AML, seven with MDS and nine with CML) older than 55 years who were given a fludarabine-based RIC regimen (with or without anti-thymocyte globulin (ATG)), followed by a graft obtained from an unrelated donor. Median follow-up was 27 months, 1-year OS and event-free survival were 44 and 37%. Although the relapse rate was low at 11%, 100-day TRM was 38% and acute and chronic GVHD rates were 41 and 63%, respectively. Patients receiving ATG had a trend to better survival. Patients transplanted at the time of refractory disease had worse outcomes. TRM was relatively high, reflecting a more intense RIC approach, high rate of GVHD and the advanced age of patients.
The MD Anderson group further attempted to determine whether a more intense preparative regimen would be useful in elderly myeloid malignancy patients. 58 Ninetyfour patients (n ¼ 68 AML and n ¼ 26 MDS) received one RIC regimen with fludarabine and melphalan versus a fludarabine, low-dose cytarabine and idarubicin approach. The more intense regimen was associated with a higher 3-year TRM of 39% compared to 15% in the less intensively treated group. On the other hand, the less intense regimen was associated with a higher relapse rate, despite the greater prevalence of low-risk patients in that group, that is, a 3-year relapse rate of 53 versus 26%. Another study by this group was a historic case-control comparison in elderly AML and MDS patients. 59 Untreated AML patients older than 50 years, with unfavourable cytogenetics, were evaluated for a RIC transplant while in CR1. Ninetynine of 259 patients attained CR and a histocompatible donor was identified for 26 (n ¼ 21 related; n ¼ 5 unrelated) subjects. An RIC transplant was performed in 14 patients using a related (n ¼ 13) and an unrelated donor (n ¼ 1). Transplanted patients were compared to patients matched for age and cytogenetics, but who received only chemotherapy. Relapse-free survival time and OS were superior in those CR1 patients who received an RIC transplant compared to those given conventional chemotherapy.
Other initiatives
Refractory AML patients have an extremely poor prognosis, especially the elderly, even if stem cell transplantation is employed. 60 Schmid et al. 61 treated 103 refractory AML patients (median age 52 years) using a sequential regimen of conventional chemotherapy, immediately followed by an RIC transplant and prophylactic infusion of donor lymphocytes. Results were encouraging, as 4-year OS and LFS rates were 32 and 30%, respectively. Claxton et al. 62 reported a similar strategy and excellent results as well.
Three groups focused on using a preparative regimen containing anti-lymphocyte antibodies, [63] [64] [65] usually alemtuzumab or ATG. These efforts addressed TRM as being related to high rates of acute and chronic GVHD that appear higher in older patients as compared to younger ones. 66 Tauro et al. 63 recently published the British experience in 77 high-risk AML and MDS patients, who received an allograft using fludarabine, melphalan and alemtuzumab as preparation. Median age was 52 years; for the AML patients, 22 were grafted in CR1 and 34 beyond CR1; 20 MDS were enrolled. Values for 100-day and 1-year TRM were 9 and 19%, respectively. Median follow-up was 36 months and for the entire group, the relapse rate was 35%. The incidence of acute and chronic GVHD was low at 28 (no grade 3 or 4) and 10%, respectively. Relapse rates, however, remained high, an expected trade-off for using alemtuzumab to reduce GVHD, but likely blunting graftversus-leukaemia effect. Two other groups investigated the use of anti-lymphocyte antibodies as part of the preparative regimen 64, 65 (see Table 4 ). Popat et al. 64 treated 17 consecutive patients using TBI 450 cGy, fludarabine, and either ATG, alemtuzumab or a monoclonal anti-CD45 antibody. Although GVHD rates were relatively low, again relapses remained high. Similar results in 26 AML and MDS patients were observed by Kroger et al., 65 using treosulfan, fluadarbine and ATG as preparation.
Future considerations
Elderly patients with AML have a distinct disease biology leading to different outcomes, as compared to younger patients. Comorbidities of older patients usually are more significant and their tolerance to intense chemotherapy is diminished. Novel treatment regimens should take into account the higher degree of resistance of leukaemic cells to standard chemotherapy in this patient population by, for example, using treatment combinations including so-called 'targeted therapies' that may include radioimmunoconjugates or image-guided total marrow irradiation, that is, helical tomotherapy. 67 Tools to better predict which patients may be able to tolerate intense treatment are being developed. Stem cell transplantation is an important modality in treatment of selected elderly AML patients. Both autologous and allogeneic myeloablative transplant procedures, however, are applicable only to a minority of patients. A balance has to be struck between attempts of decreasing toxicity of the procedures and an increased relapse rate risk related to suboptimal disease control. One interesting, single-centre approach reported by the Johns Hopkins group involves using a myeloablative allogeneic transplant regimen consisting of busulfan and cyclophosphamide, but without using post-transplant immunosuppressive agents; instead cyclophosphamide 50 mg/kg/day is given on days 3 and 4 after the stem cell infusion. 68 Their series includes some elderly patients and they report low TRM and GVHD rates. These results need to be confirmed in a larger patient, multi-centre trial that includes longer follow-up.
Non-myeloablative stem cell transplants are feasible and promising. The optimal conditioning regimens still need to be developed and the procedure must be validated in prospective trials compared to non-transplant treatment strategies. The Trans Atlantic Leukemia study group currently is undertaking a multi-centre, multinational trial prospectively comparing patients undergoing standard post-remission therapy versus a non-myeloablative allogeneic stem cell transplant. This type of trial can help answer the question of whether a transplant approach is preferable to non-transplant approaches (Drs M Brune, Goetheborg, R Delage, Quebec City and T Kiss, Montreal, personal communications).
